|
India has made substantial advancements in Nipah virus diagnostic testing. Laboratories now use molecular methods that include real-time reverse transcription polymerase chain reaction (RT-PCR) and serological tests to achieve their standard laboratory testing process. The need to use central testing centres results in testing delays that create problems for doctors who need to make urgent medical evaluations, according to Dr. Sameer Bhati, director, Anand Imaging and Diagnostics.
The Nipah virus (NiV) remains a serious public health threat in India because of its high death rate and its ability to spread from animals to humans and between people. The country has experienced multiple outbreaks over the years which have demonstrated that Kerala and West Bengal require active monitoring and quick identification and efficient medical response systems.
Dr. Bhati explains, "Nipah virus exists as one of the most perilous emerging infectious diseases because it spreads through direct contact and has a high death rate. The process of identifying cases in their early stages together with immediate patient isolation measures stands as the most effective method to stop further disease spread.”
A major advancement in this area is the development of a portable “lab-in-a-box” diagnostic kit by the National Institute of Virology (NIV), Pune. The compact system enables healthcare workers to diagnose Nipah virus infections in remote villages and outbreak-prone areas, which eliminates the need to wait for sample results that travel to major cities. Dr Bhati states that this innovation provides faster case confirmation and faster establishment of containment measures.
Another important development in diagnostics is the adoption of specialized magnetic resonance imaging (MRI) techniques to identify characteristic patterns of brain involvement in Nipah encephalitis. The enhanced imaging markers enable physicians to differentiate Nipah virus infection from Japanese Encephalitis and other viral encephalitis’s which present similar neurological symptoms thus enabling timely proper treatment for patients.
Health experts note that ecological changes and deforestation together with rising human-animal contact have increased the possibility of spillover events from fruit bats which serve as the main virus reservoirs. The outbreak management system requires laboratory infrastructure development together with improved diagnostic skills which serve as its main operational component.
Dr Bhati informs that there is currently no antiviral treatment that has received approval for use against Nipah virus infections. The clinical approach to treatment requires intensive medical support which includes maintenance of airway functions and oxygen levels and control of seizures and treatment of additional infections. Although Ribavirin has been used during some outbreaks through compassionate use its effectiveness for treatment remains unproven.
He further informs that the experimental monoclonal antibody treatment m102.4 has demonstrated positive results through emergency use testing which is currently undergoing further assessment. Scientists are conducting research to create both vaccines and specific antiviral treatments which target the Nipah virus.
Dr Bhati emphasizes that preparedness remains the cornerstone of Nipah virus control. The implementation of surveillance system enhancements together with advanced diagnostic accessibility and healthcare professional training and public education on risk reduction methods will help decrease future outbreak impacts.
“By making continuing investments in research, diagnostic facilities, and healthcare infrastructure, the potential to detect the emergence of the Nipah virus in its early stages, thereby limiting the public health consequences, is being continuously enhanced,” Dr Bhati concludes.
|